Intraperitoneal α-Interferon Alternating with Cisplatin in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study
- 31 July 1999
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 74 (1), 48-52
- https://doi.org/10.1006/gyno.1999.5455
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Intraperitoneal immunotherapy for ovarian cancer with alpha interferonEuropean Journal Of Cancer, 1992
- Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferonGynecologic Oncology, 1992
- Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-α or interferon-α plus chemotherapy in vivo and in vitroEuropean Journal of Cancer and Clinical Oncology, 1991
- A phase I–II trial of intraperitoneal cisplatin and α-lnterferon in patients with persistent epithelial ovarian cancerGynecologic Oncology, 1990
- Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Human leukocyte interferon therapy for advanced ovarian carcinomaAmerican Journal of Clinical Oncology, 1982
- SENSITIVITY OF HUMAN OVARIAN CARCINOMA CELLS TO INTERFERON AND OTHER ANTITUMOR AGENTS AS ASSESSED BY AN IN VITRO SEMI‐SOLID AGAR TECHNIQUE*Annals of the New York Academy of Sciences, 1980